NCT04728932View on ClinicalTrials.gov

LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

November 9, 2024

Study Completion Date

November 9, 2024

Conditions
Cardiogenic ShockExtracorporeal Membrane Oxygenation Complication
Interventions
DRUG

Levosimendan

A continuous infusion of Levosimendan over 24h

DRUG

Placebo of Levosimendan

A continuous infusion of Placebo of Levosimendan over 24h

Trial Locations (3)

75013

Hôpital Pitié Salpêtrière, Paris

Unknown

Hôpital du Haut-Lévêque, Pessac

Hôpital Européen Georges Pompidou, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04728932 - LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients | Biotech Hunter | Biotech Hunter